Skip to content
OpenCapital
Get started

Viridian Therapeutics, Inc. VRDN Available For Sale Securities Debt Securities Current

Available For Sale Securities Debt Securities Current at other companies

Nektar Therapeutics logo
Nektar TherapeuticsNKTR
——
Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
——
Krystal Biotech, Inc. logo
Krystal Biotech, Inc.KRYS
——
BridgeBio Pharma logo
BridgeBio PharmaBBIO
——
ALN
Alnylam PharmaceuticalsALNY
——
Viking Therapeutics logo
Viking TherapeuticsVKTX
——

Other financials

Income statement

See full
Revenue$141.0K+95.8%
Operating income-$116.2M-23.8%
Net income-$104.9M-20.7%
EPS (diluted)-$1.15-5.5%

Balance sheet

See full
Cash & equivalents$176.3M+51.7%
Total debt$36.8M+59.4%
Total equity$636.0M+5.2%
Total assets$789.0M+19.4%

Cash flow

See full
Operating cash flow-$119.7M-29.1%
CapEx$23.0K-73.3%
Free cash flow-$119.7M-29.0%

Valuation

See full
Market cap$1.91B+82.0%
Enterprise value$1.77B+85.0%
P/S26.9×-3,445×

Profitability

See full
Gross margin36.3%—
Operating margin-543.9%-271pp
Net margin-508.5%-254pp
FCF margin-428.4%-214pp

Returns & leverage

See full
Return on equity-58.1%+7.9pp
Debt / equity0.1×0.0×
Current ratio15.1×-4.3×

Where this comes from

Reported directly by Viridian Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent.

The official record: Viridian Therapeutics, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Viridian Therapeutics, Inc.'s available for sale securities debt securities current.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Viridian Therapeutics, Inc.'s available for sale securities debt securities current?
Viridian Therapeutics, Inc. (VRDN) reported available for sale securities debt securities current of $585.84M in Q1 2026.
How has Viridian Therapeutics, Inc.'s available for sale securities debt securities current changed year-over-year?
Viridian Therapeutics, Inc.'s available for sale securities debt securities current increased by 12.6% year-over-year, from $520.42M to $585.84M.
What is the long-term trend for Viridian Therapeutics, Inc.'s available for sale securities debt securities current?
Over 4 years (2021 to 2025), Viridian Therapeutics, Inc.'s available for sale securities debt securities current has grown at a 43.9% compound annual growth rate (CAGR), from $154.67M to $662.27M.